Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Dexcom Inc (NQ: DXCM )

129.37 -8.64 (-6.26%)
Streaming Delayed Price Updated: 10:59 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Dexcom Inc

< Previous 1 2 3 4 Next >
Dexcom Reports First Quarter 2024 Financial Results
From DexCom, Inc.
Via Business Wire
Dexcom Publishes Annual Sustainability Report
From DexCom, Inc.
Via Business Wire
Dexcom Schedules First Quarter 2024 Earnings Release and Conference Call for April 25, 2024 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
DexCom Stock Gains from GLP-1 Diabetic Users
DexCom Inc. (NASDAQ: DXCM) is a leading medical device company in the medical sector that specializes in continuous glucose monitoring (CGM) systems. People 
Via MarketBeat
Stelo by Dexcom First Glucose Biosensor to be Cleared by FDA as Over-the-Counter
From DexCom, Inc.
Via Business Wire
Dexcom Announces Upcoming Conference Presentation
From DexCom, Inc.
Via Business Wire
Wall Street is surprisingly most bullish on these 3 Nasdaq stocks
Analysts are gradually shifting toward underperforming, less prominent names to find the next big thing - including these three current Wall Street faves 
Via MarketBeat
Dexcom Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From DexCom, Inc.
Via Business Wire
3 Nasdaq stocks likely to make big earnings splashes
Here we look at a few examples of high beta, high standard deviation Nasdaq-100 stocks that are poised to have volatile earnings moves in the near future. 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
Dexcom Schedules Fourth Quarter and Fiscal Year 2023 Earnings Release and Conference Call for February 8, 2024 at 4:30 p.m. Eastern Time
From DexCom, Inc.
Via Business Wire
MarketBeat ‘Stock of the Week’: Intuitive Surgical hits new highs
With recent obesity drug fears proving to be overblown and equipment placements growing, expect ISRG to reward growth investors with plenty more record highs. 
Via MarketBeat
Topics Earnings
Exposures Financial
Dexcom Reports Preliminary, Unaudited Revenue for the Fourth Quarter and Fiscal Year 2023 and Initial 2024 Outlook
From DexCom, Inc.
Via Business Wire
HCA Healthcare Rallies: Weight-loss drugs really a big threat?
HCA Healthcare rebounds amid concerns about weight-loss drugs' impact. The healthcare giant's revenue growth hints at resilience despite sector challenges. 
Via MarketBeat
Topics ETFs
Dexcom to Present at 42nd Annual J.P. Morgan Healthcare Conference
From DexCom, Inc.
Via Business Wire
Dexcom G7 is Now the Most Accurate, Smallest, Easy-to-Use CGM Connected to the Tandem t:slim X2 Insulin Pump
From DexCom, Inc.
Via Business Wire
Dexcom Announces Upcoming Conference Presentation
From DexCom, Inc.
Via Business Wire
Dexcom Unveils Portrait Gallery to Portray Emotional Highs and Lows of Living With Diabetes on World Diabetes Day
From DexCom, Inc.
Via Business Wire
Dexcom Reports Third Quarter 2023 Financial Results, Raises 2023 Revenue and Margin Guidance, and Announces $500 Million Share Repurchase Program
From DexCom, Inc.
Via Business Wire
Global Diabetes Care Market Size Expected To Reach $41.71 Billion By 2027
EQNX::TICKER_START (OTCPK:CNER),(NYSE:NVO),(NASDAQ:TNDM),(NASDAQ:DXCM),(NASDAQ:LXRX) EQNX::TICKER_END 
Via FinancialNewsMedia
MarketBeat Week in Review – 10/16 - 10/20
All the major indexes moved lower on Friday, making it a near certainty that stocks would post their worst week in a month; the bears are firmly in control 
Via MarketBeat
Topics Bonds Economy
Exposures Debt Markets Economy Interest Rates
3 Nasdaq-100 Stocks Trading Less Than 10x 2024 Earnings
These three Nasdaq-100 stocks can be had for less than 10x 2024 earnings - extra compelling given that Wall Street expects Nasdaq profits will grow next year. 
Via MarketBeat
Topics Bonds Economy
Exposures Debt Markets Interest Rates
Is the Ozempic-Driven DexCom Selloff Overdone?
Has glucose monitor maker DexCom corrected too much on fears of lost sales due to weight loss and diabetes drugs made by Novo Nordisk and Eli Lilly? 
Via MarketBeat
Dexcom Solidifies Global Leadership in Continuous Glucose Monitoring With New Clinical Data Presented at EASD
From DexCom, Inc.
Via Business Wire
Dexcom Schedules Third Quarter 2023 Earnings Release and Conference Call for October 26, 2023 at 4:30 p.m. Eastern Time.
From DexCom, Inc.
Via Business Wire
Dexcom U Kicks off 2023 Season With Expanded Roster of Athletes With Diabetes, Building on First-of-its-Kind NIL Program
From Dexcom, Inc.
Via Business Wire
Why Analysts Say GE's Healthcare Spinoff Has $20 Upside
General Electric’s spinoff, GE HealthCare Technologies Inc., is delivering some impressive results and has growth opportunities well worth tuning in to. 
Via MarketBeat
Dexcom Announces Upcoming Conference Presentations
From DexCom, Inc.
Via Business Wire
Dexcom Appoints Rimma Driscoll to Board of Directors
From DexCom, Inc.
Via Business Wire
Glucose Monitor Maker DexCom In Buy Zone After Gapping Higher
Strong Q2 earnings performance propelled DexCom higher. Investors cheered the glucose monitoring leader's bullish sales view and international expansion plans. 
Via MarketBeat
Dexcom Reports Second Quarter 2023 Financial Results
From DexCom, Inc.
Via Business Wire
< Previous 1 2 3 4 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.